U.S. market Open. Closes in 5 hours 28 minutes

HROWM | Harrow Health, Inc. 11.875% Senior Notes due 2027 Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 26.13 - 26.13
52 Week Range 22.71 - 27.72
Beta N/A
Implied Volatility N/A
IV Rank N/A
Day's Volume 364
Average Volume 3,293
Shares Outstanding 62,166,662
Market Cap 1,624,414,878
Sector Healthcare
Industry Medical - Pharmaceuticals
IPO Date 2022-12-29
Valuation
Profitability
Growth
Health
P/E Ratio N/A
Forward P/E Ratio N/A
EPS N/A
1YR Price Target N/A
Dividend Yield 11.41%
Dividend Per Share 2.98
Dividend ExDate N/A
Dividend PayDate N/A
Employees 217
Country USA
Website HROWM
Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.
HROWM's peers: HROWL, BWSN, RWAYZ, RWAYL, SCCG
*Chart delayed
Analyzing fundamentals for HROWM we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is bad and Health is passable. For more detailed analysis please see HROWM Fundamentals page.

Watching at HROWM technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on HROWM Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙